The Japanese firm will takeover Beam Inc, maker of Jim Beam, in a deal that will create a joint business that will be the world’s third largest high-end spirits manufacturer and a new company called ...

Beam Suntory has seen some trading down lately in the U.S., Suntory Holdings CEO Takeshi Niinami said in an interview with Yahoo Finance late last week, but believes premiumization remains the right ...

Kevin covers retail, airports, and the global traveling shopper. Beam Suntory is preparing to bring a series of showcase Japanese whisky pop-ups to its top duty-free and travel-retail locations ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Beam Suntory believes in ‘growing for good’. People are at the heart of its mission, whether it’s the talent behind the brand or the community that surrounds it. The world leader in premium spirits is ...

Some of the key players profiled in the study are Beam Suntory Inc (United States), Brown Forman Corporation (United States), Diageo (United Kingdom), Gruppo Campari (Italy), Heaven Hill Brands ...

The company has a pipeline of innovation planned for 2025 and beyond, across its entire brand portfolio ...

*Based on data released by the Federal Election Commission on September 08, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

H.C. Wainwright has recently initiated Beam Therapeutics Inc (BEAM) stock to Buy rating, as announced on July 23, 2024, according to Finviz. Earlier, on January 29, 2024, JP Morgan had raised the ...

H.C. Wainwright has recently initiated Beam Therapeutics Inc (BEAM) stock to Buy rating, as announced on July 23, 2024, according to Finviz. Earlier, on January 29, 2024, JP Morgan had raised the ...

Boston Beer (NYSE:SAM) soared 19% amid a report that it's in talks to be sold to Jim Beam owner Suntory (OTCPK ... The Boston ...

July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief ...